Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 9Gastrointestinal 3Thoracic 2Plasma cell 2Head & Neck 2CNS 2NET 1Lymphoid 1Gynecologic 1Genitourinary 1Endocrine 1Breast 1

Conditions

Lymphoma 2983Precursor Cell Lymphoblastic Leukemia-Lymphoma 2499Lymphoma, Non-Hodgkin 2269Leukemia, Lymphocytic, Chronic, B-Cell 1992Lymphoma, Follicular 1848Lymphoma, Large B-Cell, Diffuse 1785Leukemia 1341Hodgkin Disease 1293Lymphoma, Mantle-Cell 1193Leukemia, Myeloid, Acute 979Burkitt Lymphoma 956Multiple Myeloma 866Lymphoma, B-Cell, Marginal Zone 853Recurrence 841Lymphoma, B-Cell 756Myelodysplastic Syndromes 683Neoplasms 595Lymphoma, T-Cell, Cutaneous 543Waldenstrom Macroglobulinemia 514Lymphoma, Large-Cell, Immunoblastic 490Mycosis Fungoides 438Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 414Lymphoma, Large-Cell, Anaplastic 390Sezary Syndrome 364Lymphoma, T-Cell, Peripheral 352Hematologic Neoplasms 351Leukemia, Myelogenous, Chronic, BCR-ABL Positive 334Myeloproliferative Disorders 328Neoplasms, Plasma Cell 309Blast Crisis 284

Interventions

repotrectinib 1Suspensions 1Capsules 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solitary Fibrous Tumors × Lymphoid × Clear all
NCT04094610 2025-11-19

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
75 enrolled
CNSLymphoidPlasma cellSarcoma

Glioblastoma, Glioma, Granuloma, Plasma Cell, Lymphoma, Neoplasm Metastasis, Sarcoma, Lymphoma, Large-Cell, Anaplastic, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡